Participants 352 477 4
patients with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy.
Participants 478 689 4
Patients with epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving ramucirumab
Participants 866 965 4
f 1,253 patients with metastatic NSCLC previously treated with a platinum-based combination therapy
Participants 1933 2054 4
 of patients with metastatic non-small cell lung cancer whose disease has progressed on or after platinum-based chemother
Participants 2114 2148 3
 in patients with squamous cell tu
Participants 2230 2349 3
 in patients with tumors harboring epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrat
